Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K062870
    Manufacturer
    Date Cleared
    2006-10-20

    (25 days)

    Product Code
    Regulation Number
    870.1250
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    TRIACTIV FX EMBOLIC PROTECTION SYSTEM, MODEL PN 60040-02; -03

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The TriActiv FX® Embolic Protection System is indicated for use in conjunction with percutaneous coronary intervention (PCI), using a 7F guide catheter (without side holes), of diseased saphenous vein coronary bypass grafts ranging from 3.0mm to 5.0m in diameter. The TriActiv FX® Embolic Protection System is intended to protect the distal coronary vasculature by trapping and extracting thrombotic and atheromatous debris liberated during PCI.

    The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral, carotid, or peripheral vasculature; native coronary arteries; or for treatment of patients with acute myocardial infarction.

    Device Description

    The TriActiv FX® Embolic Protection System is a temporary balloon occlusion embolic protection device used during percutaneous coronary intervention of diseased saphenous vein grafts ranging from 3.0mm to 5.0mm in diameter. The device is comprised of four principal components: ShieldWire™ Balloon Guidewire ("balloon guidewire), ShieldWire™ Inflator ("inflator"), FX™ Catheter ("flush catheter"), and AutoStream™ Flow Control ("flow control"). There are also four subcomponents or accessories included in the TriActiv FX® Embolic Protection the Split Tube Introducer, Shieldwire™ Guidewire Plug and Installer, System: TriActiv® Flow Control Power Supply and TriActiv® Tuohy. All TriActiv FX® Embolic Protection System components are supplied sterile and for single use only with exception of the TriActiv® Flow Control Power Supply which is non-sterile and reusable.

    The balloon guidewire is advanced through the hospital-supplied 7F guide catheter (without sideholes) prior to percutaneous coronary intervention of a saphenous vein araft (SVG) and positioned just past the target lesion. The balloon is inflated with a medical grade carbon dioxide gas blend, creating a protected space between the quide catheter and the balloon. Once the balloon is inflated and vessel occlusion is confirmed, PTCA and/or stenting can be performed over the balloon guidewire. Immediately after intervention, the flush catheter is loaded on the balloon guidewire and advanced into the graft. With the flush catheter positioned just proximal to the balloon, the flow control delivers saline through the flush catheter to gently wash the vessel and remove any debris generated during the intervention through the guide catheter into a collection bag. The TriActiv FX® Embolic Protection System has been designed to extract at a greater rate than it infuses to prevent aortic embolization. Once the physician is satisfied with the amount of debris removed from the vessel, the protection balloon is deflated and the device is removed.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the TriActiv FX® Embolic Protection System, based on the provided 510(k) summary:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria for the TriActiv FX® Embolic Protection System were primarily established through a non-inferiority comparison to existing predicate devices (Medtronic Guardwire® or Boston Scientific Filterwire EX™). The key performance metrics are related to Major Adverse Cardiac Events (MACE) and other clinical outcomes.

    Metric (Acceptance Criteria)Reported Device Performance (TriActiv FX® - ASPIRE Study)Reference Device Performance (Guardwire® / Filterwire EX™ - PRIDE Study)Adjusted P-ValueUnadjusted Difference (95% CI)
    MACE to 30 days (Non-inferiority to predicate)3.2% (3/93)10.1% (32/318)0.013-6.8% (-2.7%)
    Myocardial Infarction (MI) (Lower rate desired)2.2% (2/93)8.8% (28/318)0.021-6.7% (-3.1%)
    Device Success⁴95.7% (89/93)94.5% (293/310)0.791.2% (-2.9%)
    Procedure Success/Patient⁵ (Criteria for successful procedure)97.8% (90/92)90.5% (286/316)0.0137.3% (3.6%)
    Lesion Success/Lesion⁶ (Criteria for successful lesion treatment)100% (103/103)99.4% (319/321)-0.6% (-0.1%)
    Final TIMI Flow 00% (0/97)0.6% (2/306)0.98-
    Final TIMI Flow 10% (0/97)0.6% (2/306)--
    Final TIMI Flow 24.1% (4/97)0.9% (3/306)--

    ⁴ Device success is defined as attainment of all of the following: the device was successfully delivered to the target location, the device operated as intended, the device was successfully retrieved.
    *⁵ Final stenosis

    Ask a Question

    Ask a specific question about this device

    K Number
    K061772
    Manufacturer
    Date Cleared
    2006-07-11

    (18 days)

    Product Code
    Regulation Number
    870.1250
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    TRIACTIV FX EMBOLIC PROTECTION SYSTEM

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The TriActiv FX® Embolic Protection System is indicated for use in conjunction with percutaneous coronary intervention (PCI), using a 7F guide catheter (without side holes), of diseased saphenous vein coronary bypass grafts ranging from 3.0mm to 5.0m in diameter. The TriActiv FX® Embolic Protection System is intended to protect the distal coronary vasculature by trapping and extracting thrombotic and atheromatous debris liberated during PCI.

    The safety and effectiveness of this device as an embolic protection system has not been established in the cerebral, carotid, or peripheral vasculature; native coronary arteries; or for treatment of patients with acute myocardial infarction.

    Device Description

    The TriActiv FX® Embolic Protection System is a temporary balloon occlusion embolic protection device used during percutaneous coronary intervention of diseased saphenous vein grafts ranging from 3.0mm to 5.0mm in diameter. The device is comprised of four principal components: ShieldWire™ Balloon Guidewire ("balloon guidewire), ShieldWire™ Inflator ("inflator"), FX™ Catheter ("flush catheter"), and AutoStream™ Flow Control ("flow control"). There are also four subcomponents or accessories included in the TriActiv FX® Embolic Protection System: the Split Tube Introducer, Shieldwire™ Guidewire Plug and Installer, TriActiv® Flow Control Power Supply and TriActiv® Tuohy. All TriActiv FX® Embolic Protection System components are supplied sterile and for single use only with exception of the TriActiv® Flow Control Power Supply which is non-sterile and reusable.

    AI/ML Overview

    The provided text describes the TriActiv FX® Embolic Protection System and its clinical evaluation, but it does not include a table of acceptance criteria or explicitly state acceptance criteria for device performance. It focuses on demonstrating non-inferiority to a predicate device based on clinical outcomes.

    However, based on the clinical study results presented, we can infer what the implicit performance goals or "acceptance criteria" likely were, particularly in relation to the predicate device.

    Here's an attempt to structure the information based on your request, inferring where explicit details are missing:


    1. Table of Acceptance Criteria and Reported Device Performance

    Since explicit acceptance criteria are not presented in a table in the submission, the table below infers the performance goals based on the non-inferiority study results compared to the predicate. The "Acceptance Criteria" here are derived from the need to demonstrate non-inferiority to the Active Control Arm of the PRIDE Trial (using Guardwire® Plus System or FilterWire® EX System).

    Performance MetricAcceptance Criteria (Implied for Non-Inferiority)Reported Device Performance (ASPIRE Enrollment Phase)Did the Device Meet Criteria?
    Major Adverse Cardiac Events (MACE) to 30 daysNon-inferior to predicate (Active Control Arm MACE rate: 10.1%)3.2% (3/93)Yes (p
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1